Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02203864 | Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma | completed | Phase 1 | 49 | Boehringer IngelheimINDUSTRY | 0 | Jul 31, 2014 | clinicaltrials |
| NCT00132704 | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | completed | — | 149 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2014 |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01573494 | Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma | completed | N/A | 30 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 26, 2014 | clinicaltrials |
| NCT00920907 | Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma | completed | Phase 1 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 20, 2014 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00623766 | Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases | completed | Phase 2 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy(LAK) | terminated | — | 11 | Loma Linda UniversityOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00003274 | Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00003339 | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00025181 | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00028431 | Novel Adjuvants for Peptide-Based Melanoma Vaccines | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00031733 | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | completed | Phase 2 | 60 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00085189 | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00334776 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 6 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00669019 | Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00281957 | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00816374 | Tailored Intervention for Melanoma Patient's Families | completed | N/A | 553 | Fox Chase Cancer CenterOTHER | 1 | May 16, 2014 | clinicaltrials |
| NCT00436605 | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00651157 | Viral Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2014 | clinicaltrials |
| NCT01339663 | Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00349206 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2014 | clinicaltrials |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Ludwig Institute for Cancer ResearchOTHER | 0 | Apr 1, 2014 | clinicaltrials |
| NCT01014351 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00004135 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | completed | Phase 2 | 19 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00184275 | Characterization of Brain Metastases | completed | — | 26 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00084214 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | completed | Phase 1 / Phase 2 | 103 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | terminated | Phase 3 | 630 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Mar 4, 2014 | clinicaltrials |
| NCT02074605 | Cognitive Effects of Interferon in Patients With Melanoma | completed | — | 36 | University of ArizonaOTHER | 1 | Feb 28, 2014 | clinicaltrials |
| NCT00631618 | Clinical Trial of Sutent to Treat Metastatic Melanoma | completed | Phase 2 | 12 | California Pacific Medical Center Research InstituteOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | terminated | Phase 2 | 102 | Philogen S.p.A.INDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT00313508 | Dendritic Cell Vaccination During Lymphoid Reconstruction | completed | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 21, 2014 | clinicaltrials |
| NCT01933061 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | withdrawn | Phase 2 | 0 | Celgene CorporationINDUSTRY | 0 | Feb 4, 2014 | clinicaltrials |
| NCT00012064 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | completed | Phase 1 / Phase 2 | 56 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00672542 | Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells | completed | Phase 1 | 12 | Scott PruittOTHER | 1 | Jan 23, 2014 | clinicaltrials |
| NCT00004196 | Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | completed | Phase 3 | 3,000 | University of Alabama at BirminghamOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2014source: clinicaltrials